| Skip navigation | ||
![]() |
![]() | ![]() |
|
|
||
Primary lymphoma of the brain is cancer of the lymph cells that starts in the brain.
The cause of primary brain lymphoma is unknown. It is more common in people ages 45 - 70.
Patients who have a weakened immune system are at greater risk for primary lymphoma of the brain. Common causes of a weakened immune system include:
Lymphoma is also linked to Epstein-Barr Virus (EBV) infection, the virus that causes mononucleosis.
The incidence of primary brain lymphoma is rising, but it is still relatively rare.
The following tests may be performed to help diagnose a primary lymphoma of the brain:
The condition is usually first treated with corticosteroids. However, chemotherapy may increase survival by 3 - 4 years, or longer. The chemotherapy is usually high doses of methotrexate given through a vein (intravenously) or a spinal tap.
Treating patients with weakened immune systems is not as successful, but it is improving.
Radiation therapy used to be the main treatment for primary lymphoma of the brain. Now it is usually reserved for treating patients who do not respond to chemotherapy.
Treatment with multiple therapies (combination therapy) is common.
The survival of untreated primary brain lymphoma is under 2 months. Treated with chemotherapy, patients often survive 3 - 4 years or more. About 40% of patients are alive at 5 years. In general, older patients have a worse outlook than younger patients.
Possible complications include:
Brain lymphoma; Cerebral lymphoma; Primary lymphoma of the central nervous system; Lymphoma - brain
DeAngelis LM. Tumors of the central nervous system and intracranial hypertension and hypotension. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 199.
National Cancer Institute. Primary CNS lymphoma treatment (PDQ). 2009. Accessed February 25, 2009.
Updated by: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
|
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch). |

| Home | Health Topics | Drugs & Supplements | Encyclopedia | Dictionary | News | Directories | Other Resources | |
| Disclaimers | Copyright | Privacy | Accessibility | Quality Guidelines U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health | Department of Health & Human Services |
Page last updated: 29 October 2009 |